Manufacturing, Biosimilars and Biobetters

Reviewing the Importance of Biosimilarity and Interchangeability

June 06, 2024

Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.

Teva Pharmaceuticals and Alvotech Expand Existing Biosimilars Partnership

July 27, 2023

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

mRNA Global Alliance Tests the Waters at BIO

June 12, 2023

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the US goal to design, test, and review a new vaccine just 100 days after a pandemic declaration.

Biosimilar CDMO Capacity Increased in Samsung Biologics – Pfizer’s New Arrangement

June 08, 2023

The collaboration between Samsung Biologics and Pfizer will focus on long-term biosimilars manufacturing.

Sandoz and Just – Evotec Biologics Form Biosimilars Pact

May 12, 2023

The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.

Sandoz to Build New Biologics Production Facility in Slovenia

March 17, 2023

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Biogen and Xbrane Ink Agreement for Proposed Biosimilar

February 17, 2022

The commercialization and licensing deal will see Biogen commercialize Xbrane’s Xcimzane, a proposed biosimilar for CIMZIA (certolizumab pegol).

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal

January 28, 2022

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Sandoz Begins Late-Stage Clinical Development for Biosimilar Aflibercept

May 07, 2021

Sandoz will soon begin enrolling patients with neovascular age-related macular degeneration in a Phase III study with its proposed biosimilar to aflibercept.

Henlius and Accord Healthcare Receive European Approval for Biosimilar Trastuzumab

August 13, 2020

The companies received approval from the EC for Zercepac (HLX02), a biosimilar referencing Roche’s originator biologic, Herceptin (trastuzumab).